SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Peter, K. Articles by Bode, C. Search for Related Content PubMed PubMed Citation Articles by Peter, K. Articles by Bode, C. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 92 No. 9 (November 1), 1998: pp. 3240-3249 Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIb3) Inhibitors Karlheinz Peter, Meike Schwarz, Jari Ylänne, Benedikt Kohler, Martin Moser, Thomas Nordt, Peter Salbach, Wolfgang Kübler, and Christoph Bode From the Department of Internal Medicine III, University of Heidelberg, Heidelberg, Germany; and the Department of Biochemistry, University of Helsinki, Helsinki, Finland. The blockade of platelet integrin glycoprotein (GP) IIb/IIIa is a promising new antiplatelet strategy. The binding of ligands or of the ligand-mimetic peptide RGD causes a conformational change of GP IIb/IIIa from the nonactivated to the activated state. Because several blocking agents/inhibitors are ligand-mimetics, the current study evaluates whether these agents have the intrinsic property to activate GP IIb/IIIa. Fibrinogen binding to GP IIb/IIIa on platelets or on CHO cells expressing recombinant GP IIb/IIIa was evaluated by flow cytometry or 125I-labeled fibrinogen. Incubation with the monoclonal antibody (MoAb) fragment c7E3 (abciximab) results in fibrinogen binding to GP IIb/IIIa and in the access of ligand-induced binding sites. At low concentrations (0.01 to 0.1 µg/mL), this intrinsic activating property of c7E3 can result in platelet aggregation. The disintegrin flavorodin and the RGD analogue fradafiban also induce fibrinogen binding, whereas the blocking MoAbs 2G12 and P2 and the activation-specific MoAb PAC-1 do not. Aspirin and indomethacin cannot block c7E3-induced fibrinogen binding to GP IIb/IIIa, but can inhibit c7E3-induced platelet aggregation. Thus, we conclude that GP IIb/IIIa inhibitors can demonstrate an intrinsic activating property, which can result in fibrinogen binding to GP IIb/IIIa and consequently in platelet aggregation. Cyclooxygenase inhibitors can inhibit platelet aggregation caused by GP IIb/IIIa inhibitors. Further studies will have to evaluate the clinical relevance of the potential intrinsic activating property of GP IIb/IIIa inhibitors and define consequences for the future drug development and evaluation of these potent antiplatelet agents. © 1998 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF] T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF] N. Bassler, C. Loeffler, P. Mangin, Y. Yuan, M. Schwarz, C. E. Hagemeyer, S. U. Eisenhardt, I. Ahrens, C. Bode, S. P. Jackson, et al. A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic {alpha}IIb{beta}3 (GPIIb/IIIa) Antagonists Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): E9 - E15. [Abstract] [Full Text] [PDF] W.-Y. Wang, Y.-C. Wu, and C.-C. Wu Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy-beta-Nitrostyrene, A Novel Tyrosine Kinase Inhibitor Mol. Pharmacol., October 1, 2006; 70(4): 1380 - 1389. [Abstract] [Full Text] [PDF] M. Schwarz, G. Meade, P. Stoll, J. Ylanne, N. Bassler, Y. C. Chen, C. E. Hagemeyer, I. Ahrens, N. Moran, D. Kenny, et al. Conformation-Specific Blockade of the Integrin GPIIb/IIIa: A Novel Antiplatelet Strategy That Selectively Targets Activated Platelets Circ. Res., July 7, 2006; 99(1): 25 - 33. [Abstract] [Full Text] [PDF] P. Chen, C.-X. Sun, and J.-N. Liu A Novel Anti-platelet Monoclonal Antibody (3C7) Specific for the Complex of Integrin {alpha}IIb{beta}3 Inhibits Platelet Aggregation and Adhesion J. Biol. Chem., July 8, 2005; 280(27): 25403 - 25408. [Abstract] [Full Text] [PDF] R. Altman, A. Scazziota, S. Santoro, and C. Gonzalez Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 271 - 277. [Abstract] [PDF] R. H. Aster Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa Inhibitors Chest, February 1, 2005; 127(2_suppl): 53S - 59S. [Abstract] [Full Text] [PDF] P. W. Armstrong, L. K. Newby, C. B. Granger, K. L. Lee, R. J. Simes, F. Van de Werf, H. D. White, R. M. Califf, and for the Virtual Coordinating Centre for Global Col Lessons Learned From a Clinical Trial Circulation, December 7, 2004; 110(23): 3610 - 3614. [Full Text] [PDF] C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF] Z. Xiao and P. Theroux Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1982 - 1988. [Abstract] [Full Text] [PDF] M. S. Aguzzi, C. Giampietri, F. De Marchis, F. Padula, R. Gaeta, G. Ragone, M. C. Capogrossi, and A. Facchiano RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells Blood, June 1, 2004; 103(11): 4180 - 4187. [Abstract] [Full Text] [PDF] M. Schwarz, Y. Katagiri, M. Kotani, N. Bassler, C. Loeffler, C. Bode, and K. Peter Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa ({alpha}IIb{beta}3, CD41/CD61) J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1002 - 1011. [Abstract] [Full Text] [PDF] M. Dalby, G. Montalescot, C. B. d. Sollier, E. Vicaut, T. Soulat, J.-P. Collet, R. Choussat, V. Gallois, G. Drobinski, L. Drouet, et al. Eptifibatide provides additional platelet inhibition in Non-ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the platelet activity extinction in Non-Q-Wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study J. Am. Coll. Cardiol., January 21, 2004; 43(2): 162 - 168. [Abstract] [Full Text] [PDF] C. Patrono, F. Bachmann, C. Baigent, C. Bode, R. De Caterina, B. Charbonnier, D. Fitzgerald, J. Hirsh, S. Husted, J. Kvasnicka, et al. Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology Eur. Heart J., January 2, 2004; 25(2): 166 - 181. [Full Text] [PDF] M. Camera, M. Frigerio, V. Toschi, M. Brambilla, F. Rossi, D. C. Cottell, P. Maderna, A. Parolari, R. Bonzi, O. De Vincenti, et al. Platelet Activation Induces Cell-Surface Immunoreactive Tissue Factor Expression, Which Is Modulated Differently by Antiplatelet Drugs Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1690 - 1696. [Abstract] [Full Text] [PDF] M. J. Quinn, T. V. Byzova, J. Qin, E. J. Topol, and E. F. Plow Integrin {alpha}IIb{beta}3 and Its Antagonism Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 945 - 952. [Abstract] [Full Text] [PDF] M. Mirabet, D. Garcia-Dorado, J. Inserte, J. A. Barrabes, R.-M. Lidon, B. Soriano, M. Azevedo, F. Padilla, L. Agullo, M. Ruiz-Meana, et al. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1134 - H1141. [Abstract] [Full Text] [PDF] M. J. Quinn, E. F. Plow, and E. J. Topol Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword? Circulation, July 16, 2002; 106(3): 379 - 385. [Full Text] [PDF] K. Peter, M. Schwarz, C. Bode, A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, and A. D. Michelson Activating Effects of GPIIb/IIIa Blockers: An Intrinsic Consequence of Ligand- Mimetic Properties * Response Circulation, May 28, 2002; 105 (21): e180 - e181. [Full Text] [PDF] B. R. Curtis, J. Swyers, A. Divgi, J. G. McFarland, and R. H. Aster Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets Blood, March 15, 2002; 99(6): 2054 - 2059. [Abstract] [Full Text] [PDF] F.W.G. Leebeek, E. Boersma, C.P. Cannon, F.J.J. van de Werf, and M.L. Simoons Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable Eur. Heart J., March 2, 2002; 23(6): 444 - 457. [Full Text] [PDF] M.-J. Jacobin, J. Laroche-Traineau, M. Little, A. Keller, K. Peter, M. Welschof, A. Nurden, and G. Clofent-Sanchez Human IgG Monoclonal Anti-{alpha}IIb{beta}3-Binding Fragments Derived from Immunized Donors Using Phage Display J. Immunol., February 15, 2002; 168(4): 2035 - 2045. [Abstract] [Full Text] [PDF] C. Patrono Antiplatelet strategies Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A42 - A47. [Abstract] [PDF] F. F. O'Connor, D. C. Shields, A. Fitzgerald, C. P. Cannon, E. Braunwald, and D. J. Fitzgerald Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood, December 1, 2001; 98(12): 3256 - 3260. [Abstract] [Full Text] [PDF] A. L. Frelinger III, M. I. Furman, L. A. Krueger, M. R. Barnard, and A. D. Michelson Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation Circulation, September 18, 2001; 104(12): 1374 - 1379. [Abstract] [Full Text] [PDF] D. J. Fitzgerald Vascular biology of thrombosis: The role of platelet-vessel wall adhesion Neurology, September 1, 2001; 57(90002): S1 - 4. [Abstract] [Full Text] Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes Circulation, April 3, 2001; 103(13): 1727 - 1733. [Abstract] [Full Text] [PDF] F.-J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schomig, and M. Gawaz Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF] K M Akkerhuis, M J B M van den Brand, C van der Zwaan, H O J Peels, H Suryapranata, L R van der Wieken, J Stibbe, J Hoffmann, T Baardman, J W Deckers, et al. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty Heart, April 1, 2001; 85(4): 444 - 450. [Abstract] [Full Text] D. P. Chew, D. L. Bhatt, S. Sapp, and E. J. Topol Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists : A Meta-Analysis of Phase III Multicenter Randomized Trials Circulation, January 16, 2001; 103(2): 201 - 206. [Abstract] [Full Text] [PDF] J. P. Abulencia, N. Tien, O. J. T. McCarty, D. Plymire, S. A. Mousa, and K. Konstantopoulos Comparative Antiplatelet Efficacy of a Novel, Nonpeptide GPIIb/IIIa Antagonist (XV454) and Abciximab (c7E3) in Flow Models of Thrombosis Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 149 - 156. [Abstract] [Full Text] [PDF] C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF] F.W.A. Verheugt How hot is inflammation in acute coronary syndrom? Eur. Heart J., December 2, 2000; 21(24): 1990 - 1992. [PDF] R. Curtin and D.J. Fitzgerald A cold start for oral glycoprotein IIb/IIIa antagonists Eur. Heart J., December 2, 2000; 21(24): 1992 - 1994. [PDF] K. M. Akkerhuis, K.-L. Neuhaus, R. G. Wilcox, A. Vahanian, J.-L. Boland, J. Hoffmann, T. Baardman, G. Nehmiz, U. Roth, A. P. J. Klootwijk, et al. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation A phase II study Eur. Heart J., December 2, 2000; 21(24): 2042 - 2055. [Abstract] [PDF] D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF] D. Cox, R. Smith, M. Quinn, P. Theroux, P. Crean, and D. J. Fitzgerald Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1514 - 1519. [Abstract] [Full Text] [PDF] M. J. Quinn, D. Cox, J. B. Foley, and D. J. Fitzgerald Glycoprotein IIb/IIIa Receptor Number and Occupancy during Chronic Administration of an Oral Antagonist J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 670 - 676. [Abstract] [Full Text] K. Peter, B. Kohler, A. Straub, J. Ruef, M. Moser, T. Nordt, M. Olschewski, M. E. Ohman, W. Kubler, and C. Bode Flow Cytometric Monitoring of Glycoprotein IIb/IIIa Blockade and Platelet Function in Patients With Acute Myocardial Infarction Receiving Reteplase, Abciximab, and Ticlopidine : Continuous Platelet Inhibition by the Combination of Abciximab and Ticlopidine Circulation, September 26, 2000; 102(13): 1490 - 1496. [Abstract] [Full Text] [PDF] E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF] S. A. Mousa, J. M. Bozarth, M. S. Forsythe, and A. Slee Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels Cardiovasc Res, September 1, 2000; 47(4): 819 - 826. [Abstract] [Full Text] [PDF] C. P. Cannon, C. H. McCabe, R. G. Wilcox, A. Langer, A. Caspi, P. Berink, J. Lopez-Sendon, J. Toman, A. Charlesworth, R. J. Anders, et al. Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial Circulation, July 11, 2000; 102(2): 149 - 156. [Abstract] [Full Text] [PDF] D. C. Sane, L. V. Damaraju, E. J. Topol, C. F. Cabot, M. A. Mascelli, R. A. Harrington, M. L. Simoons, R. M. Califf, and EPIC EPILOG CAPTURE and EPISTENT Study Groups Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy J. Am. Coll. Cardiol., July 1, 2000; 36(1): 75 - 83. [Abstract] [Full Text] [PDF] W. W. O'Neill, P. Serruys, M. Knudtson, G.-A. van Es, G. C. Timmis, C. van der Zwaan, J. Kleiman, J. Gong, E. B. Roecker, R. Dreiling, et al. Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization N. Engl. J. Med., May 4, 2000; 342(18): 1316 - 1324. [Abstract] [Full Text] [PDF] D. J. Weiss, M. L. Mirsky, O. A. Evanson, J. Fagliari, D. Mcclenahan, and B. Mccullough Platelet Kinetics in Dogs Treated with a Glycoprotein IIb/IIIa Peptide Antagonist Toxicol Pathol, March 1, 2000; 28(2): 310 - 316. [Abstract] [PDF] D. J Schneider, D. J Taatjes, and B. E Sobel Paradoxical inhibition of fibrinogen binding and potentiation of {alpha}-granule release by specific types of inhibitors of glycoprotein IIb-IIIa Cardiovasc Res, January 14, 2000; 45(2): 437 - 446. [Abstract] [Full Text] [PDF] A. T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet Glycoprotein IIb/IIIa Inhibitors : Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2835 - 2840. [Full Text] [PDF] R. M. Scarborough, N. S. Kleiman, and D. R. Phillips Platelet Glycoprotein IIb/IIIa Antagonists : What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use? Circulation, July 27, 1999; 100(4): 437 - 444. [Abstract] [Full Text] [PDF] E. Cazes, P. Nurden, and A. T. Nurden Abciximab Binding to Glycoprotein IIb-IIIa and Protein Tyrosine Phosphorylation in Human Platelets Blood, June 1, 1999; 93(11): 4019 - 4020. [Full Text] [PDF] U. Junghans, R. J. Seitz, H. J. Wittsack, A. Aulich, and M. Siebler Treatment of Acute Basilar Artery Thrombosis with a Combination of Systemic Alteplase and Tirofiban, a Nonpeptide Platelet Glycoprotein IIb/IIIa Inhibitor: Report of Four Cases Radiology, December 1, 2001; 221(3): 795 - 801. [Abstract] [Full Text] [PDF]

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020